Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation
Author:
Affiliation:
1. Royal Free London NHS Foundation Trust, University College London, United Kingdom
2. PHMR, London, United Kingdom*
3. PHMR, London, United Kingdom
4. Takeda Development Center Americas, Lexington, Massachusetts, USA
Abstract
Publisher
The Journal of Health Economics and Outcomes Research
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference44 articles.
1. Fabrazyme, INN-agalsidase beta;European Medicines Agency
2. Galafold, INN-migalastat hydrochloride;European Medicines Agency
3. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis;Michael Beck;Molecular Genetics and Metabolism Reports,2015
4. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis;Uma Ramaswami;Drug Design, Development and Therapy,2019
5. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study;Maarten Arends;Journal of Inherited Metabolic Disease,2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3